StreetAlpha.app
Home › Stocks › PBYI

Puma Biotechnology, Inc. (PBYI)

$7.14
▼ −2.72%
LAST CLOSE · NOV 17

Puma Biotechnology develops and sells cancer treatments, including the breast cancer drug NERLYNX. It last closed at $7.14 on Nov 17, down 2.72% on the day.

AI Auto Pilots
Is PBYI in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$231.8M
+9.4% vs a year ago
Net income
$23.8M
−35.6% vs a year ago
EPS (diluted)
$0.46
−38.7% vs a year ago
Free cash flow
$46.0M
19.8% margin
Valuation
Market cap
$369.1M
51.7M shares
P/E
15.5
Price over 12 month EPS
Price to sales
1.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$41.5M
At Sep 30
Debt
$0
At Jun 30
Shareholder equity
$146.6M
Shares outstanding
51.7M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $253.2M$253.2MFY2021FY2022: $228.0M$228.0MFY2022FY2023: $235.6M$235.6MFY2023FY2024: $230.5M$230.5MFY2024FY2025: $228.4M$228.4MFY2025

From PBYI's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
—
No ratings in 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
No firm has rated PBYI in the past 90 days.
Average 12-month target
No price targets on PBYI in the past 90 days.
Latest rating changes
TD CowenMaintained
Aug 7Hold$6
DateFirmActionRatingPrice target
Aug 7TD CowenMaintainedHold$6
Loading…

Technical Analysis

PBYI · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend, oversold

The stock is 33% below its 20 day and 35% below its 50 day average. It is 13% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 24), oversold. The nearest support is the swing low (Jun 16) at $6.96, and the nearest resistance the Pivot R1 at $7.36.

Short trendBearish
Long trendBullish
MomentumWeak
StretchOversold
VolatilityHigh, 7.2%/day
Key levels
$11.5052 week high+61.1%
$9.6650 day average+35.3%
$9.5320 day average+33.5%
$9.11100 day average+27.6%
$8.04200 day average+12.6%
$7.45Swing high (May 27)+4.3%
$7.36Pivot R1+3.1%
$7.14Pivot+0.0%
$7.14Last close
$6.96Swing low (Jun 16)−2.5%
$6.92Pivot S1−3.1%
$4.8052 week low−32.8%
Indicators
RSI (14)24.09Oversold below 30Oversold
MACD-0.71Below its signal lineBearish
Stochastic4.2Near the bottom of its rangeOversold
ADX (14)31.2Trending down
Williams %R-94.6Oversold below −80, overbought above −20Oversold
CCI (20)-123.3Oversold below −100, overbought above 100Oversold
Rate of change−30.1%Change over 10 sessionsBearish
ATR (14)$0.52Typical daily range, 7.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for PBYI

What happened before

See how PBYI did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow PBYI usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How PBYI has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2012.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in PBYI in the last 90 days.

Loading…

See today’s whale options flow across the market →

PBYI Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲84 buying vs 66 selling
  • ▲Held by funds +3.2 pts
  • ▼Funds holding -4
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding157161−2.5%
In funds' top 10110.0%
Held by funds78.0%74.8%+3.2 pts
New / increased21 / 6321 / 61+2.4%
Reduced / sold out41 / 2550 / 15+1.5%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PBYI institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PBYI is in one of them and how their past PBYI trades turned out.

PBYI in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PBYI in an article yet. Here's the latest on the wider market.

PBYI Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Apr 27
Who traded PBYI · since 2019
Latest 2 filings
$1K – $15KTraded May 15, 2019Filed Apr 27, 2020
$1K – $15KTraded Jan 23, 2019Filed Apr 27, 2020
PersonTypeAmountTradedFiledDelay
Donna ShalalaD · FLSell$1K – $15KMay 15, 2019Apr 27, 2020348 d
Donna ShalalaD · FLBuy$1K – $15KJan 23, 2019Apr 27, 2020460 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Puma Biotechnology

Puma Biotechnology is a biopharmaceutical company based in Los Angeles, California, that develops and sells cancer treatments. Its main commercial product is NERLYNX, an oral form of neratinib approved in the United States for certain types of HER2 positive breast cancer. In the United States the company markets NERLYNX through its own sales force, and it works with partners in other countries to sell the drug there. It is also developing alisertib, an investigational cancer drug aimed at small cell lung cancer and hormone receptor positive breast cancer.

Headquarters
Los Angeles, CA